Cargando…

Lactoferrin and its nano-formulations in rare eye diseases

Lactoferrin (LF) is an iron-binding glycoprotein released from mucous secreting cells and neutrophils. LF can be used in a broad range of eye diseases related to the retina, cornea, and optic nerve. The retina is particularly affected by oxidative stress inside the photoreceptor being constantly exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Jiya, Sharma, Mohita, Jain, Neha, Aftab, Insha, Vikram, Naval, Singh, Tej P, Sharma, Pradeep, Sharma, Sujata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426081/
https://www.ncbi.nlm.nih.gov/pubmed/35791114
http://dx.doi.org/10.4103/ijo.IJO_303_22
_version_ 1784778603757568000
author Singh, Jiya
Sharma, Mohita
Jain, Neha
Aftab, Insha
Vikram, Naval
Singh, Tej P
Sharma, Pradeep
Sharma, Sujata
author_facet Singh, Jiya
Sharma, Mohita
Jain, Neha
Aftab, Insha
Vikram, Naval
Singh, Tej P
Sharma, Pradeep
Sharma, Sujata
author_sort Singh, Jiya
collection PubMed
description Lactoferrin (LF) is an iron-binding glycoprotein released from mucous secreting cells and neutrophils. LF can be used in a broad range of eye diseases related to the retina, cornea, and optic nerve. The retina is particularly affected by oxidative stress inside the photoreceptor being constantly exposed to light which induces accumulation of reactive oxygen species (ROS) in the retinal pigmented epithelium (RPE) causing damage to photoreceptor recycling. Retinitis pigmentosa (RP) and macular degeneration are inherited retinopathies that consist of different disease-causing genes, that cause mutations with highly varied clinical consequences. Age-related macular degeneration is a chronic disease of the retina and one of the major causes of sight loss. This review provides an application of lactoferrin and LF-based nano-formulations or nanoparticles in the field of retinal diseases or corneal diseases such as retinitis pigmentosa, retinoblastoma, age-related macular degeneration (AMD), keratoconus and uveitis. Several studies have found that lactoferrin’s antibacterial activity is not limited to its iron sequestration, but also its ability as a nanoparticle that acts as a carrier to deliver drugs by crossing the blood–retina barrier (BRB) and its involvement in cell cycle control, which is not possible by many transferrin proteins.
format Online
Article
Text
id pubmed-9426081
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-94260812022-08-31 Lactoferrin and its nano-formulations in rare eye diseases Singh, Jiya Sharma, Mohita Jain, Neha Aftab, Insha Vikram, Naval Singh, Tej P Sharma, Pradeep Sharma, Sujata Indian J Ophthalmol Review Article Lactoferrin (LF) is an iron-binding glycoprotein released from mucous secreting cells and neutrophils. LF can be used in a broad range of eye diseases related to the retina, cornea, and optic nerve. The retina is particularly affected by oxidative stress inside the photoreceptor being constantly exposed to light which induces accumulation of reactive oxygen species (ROS) in the retinal pigmented epithelium (RPE) causing damage to photoreceptor recycling. Retinitis pigmentosa (RP) and macular degeneration are inherited retinopathies that consist of different disease-causing genes, that cause mutations with highly varied clinical consequences. Age-related macular degeneration is a chronic disease of the retina and one of the major causes of sight loss. This review provides an application of lactoferrin and LF-based nano-formulations or nanoparticles in the field of retinal diseases or corneal diseases such as retinitis pigmentosa, retinoblastoma, age-related macular degeneration (AMD), keratoconus and uveitis. Several studies have found that lactoferrin’s antibacterial activity is not limited to its iron sequestration, but also its ability as a nanoparticle that acts as a carrier to deliver drugs by crossing the blood–retina barrier (BRB) and its involvement in cell cycle control, which is not possible by many transferrin proteins. Wolters Kluwer - Medknow 2022-07 2022-06-30 /pmc/articles/PMC9426081/ /pubmed/35791114 http://dx.doi.org/10.4103/ijo.IJO_303_22 Text en Copyright: © 2022 Indian Journal of Ophthalmology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Singh, Jiya
Sharma, Mohita
Jain, Neha
Aftab, Insha
Vikram, Naval
Singh, Tej P
Sharma, Pradeep
Sharma, Sujata
Lactoferrin and its nano-formulations in rare eye diseases
title Lactoferrin and its nano-formulations in rare eye diseases
title_full Lactoferrin and its nano-formulations in rare eye diseases
title_fullStr Lactoferrin and its nano-formulations in rare eye diseases
title_full_unstemmed Lactoferrin and its nano-formulations in rare eye diseases
title_short Lactoferrin and its nano-formulations in rare eye diseases
title_sort lactoferrin and its nano-formulations in rare eye diseases
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426081/
https://www.ncbi.nlm.nih.gov/pubmed/35791114
http://dx.doi.org/10.4103/ijo.IJO_303_22
work_keys_str_mv AT singhjiya lactoferrinanditsnanoformulationsinrareeyediseases
AT sharmamohita lactoferrinanditsnanoformulationsinrareeyediseases
AT jainneha lactoferrinanditsnanoformulationsinrareeyediseases
AT aftabinsha lactoferrinanditsnanoformulationsinrareeyediseases
AT vikramnaval lactoferrinanditsnanoformulationsinrareeyediseases
AT singhtejp lactoferrinanditsnanoformulationsinrareeyediseases
AT sharmapradeep lactoferrinanditsnanoformulationsinrareeyediseases
AT sharmasujata lactoferrinanditsnanoformulationsinrareeyediseases